A basket trial assessing the efficacy of the BRAF inhibitor, vemurafenib, exemplifies the importance of TOO; despite most cases carrying the BRAF V600E mutation, response rates varied widely; 0% in colorectal cancer, to 12% in cholangiocarcinoma, and 42% in NSCLC [42]. This evidence concerns the gene BRAF and cholangiocarcinoma.